Table 1 Published data from studies of GH treatment in Noonan patients
From: Five-year response to growth hormone in children with Noonan syndrome and growth hormone deficiency
Reference | No. patients (M/F) | Height SDS at start of GH treatment# | GH dose (mg/kg/week) | Duration of GH treatment (yrs) | Height SDS at last observation# |
|---|---|---|---|---|---|
Ahmed et al. 1991 [25] | 6 (3/3) | From −3.5 to −2.3 | 0.18 | 1 | - |
Thomas et al. 1993 [31] | 5 (4/1) | From −4.2 to −2.2 | 0.35 | 2.9 | From −3.3 to −1.6 |
Municchi et al. 1995 [32] | 4 (0/1) | From −1.9 to 0.2* | 0.17 | 3 | From −0.9 to 0.9* |
Cotterill et al. 1996 [33] | 30 (19/11) | −3.01 ± 0.1 | 0.33 | 1 | −2.36 ± 0.1 |
de Schepper et al. 1997 [15] | 23 (18/5) | −2.28 ± 0.68 | 0.35 | 1 | −1.78 ± 0.76 |
Soliman et al. 1998 [34] | 12 (3/9) | −2.2 ± 0.6 | 0.28 | 1 | 1.45 ± 0.3 |
MacFarlane et al. 2001 [35] | 23 (16/7) | −2.7 ± 0.4 | 0.33 | 3 | −1.9 ± 0.9 |
Ogawa et al. 2004 [36] | 15 (8/6) | −2.8 ± 0.7 | 0.17 | 2 | −2.2 ± 0.5 |
Ferreira et al. 2005 [22] | 14 (10/4) | −3.5 ± 1.0 (PTPN11 mutation) | 0.29 | 3 | 0.76 ± 0.41 (PTPN11 mutation) |
−3.4 ± 1.0 (no PTPN11 mutation) | 1.74 ± 0.10 (no PTPN11 mutation) | ||||
Binder et al. 2005 [37] | 29 (19/10) | −3.5 ± 1.0 (PTPN11 mutation) | 0.30 | 1 | 0.66 ± 0.21 (PTPN11 mutation)$ |
−3.4 ± 1.0 (no PTPN11 mutation) | 1.26 ± 0.36 (no PTPN11 mutation)$ | ||||
Osio et al. 2005 [38] | 25 (12/13) | −2.9 ± 0.4 | 0.23-0.46 | 1-9 | −1.2 ± 1.0 |
Limal et al. 2006 [23] | 35 (19/16) | −3.1 ± 0.9 (PTPN11 mutation) | 0.30-0.46 | 2 | −3.1 ± 1.4 (PTPN11 mutation) |
−2.4 ± 0.8 (no PTPN11 mutation) | −2.0 ± 0.9 (no PTPN11 mutation) | ||||
Noordam et al. 2008 [21] | 29 (21/8) | From −4.1 to −1.8 | 0.35 | 3-10.3 | From −3.0 to −0.3 |
Choi et al. 2012 [24] | 28 (14/4) | −2.8 ± 0.9 | 0.46 | 1 | −2.0 ± 0.9 |